Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?

Q Medicine

Clinical Lipidology Pub Date : 2017-01-01 DOI:10.1080/17584299.2017.1319787

A. Reiss, Nicolle M. Siegart, J. De Leon

{"title":"Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?","authors":"A. Reiss, Nicolle M. Siegart, J. De Leon","doi":"10.1080/17584299.2017.1319787","DOIUrl":null,"url":null,"abstract":"ABSTRACT Interleukin-6 (IL-6) is a unique pleiotropic cytokine exhibiting both pro- and anti-inflammatory properties depending on the target cell type. Plasma IL-6 levels are associated with cardiovascular risk. IL-6 elevation in atherosclerosis results in effects on multiple cells involved in lipid processing and plaque formation. IL-6 is also the primary determinant of acute phase protein production. IL-6 has a number of properties that foster development of cardiovascular disease. These include activation of endothelial cells, pro-thrombotic effects on platelets and promotion of smooth muscle proliferation and macrophage lipid accumulation. Despite these overall unfavourable effect on cells involved in atheroma formation, IL-6 also has a positive impact on the lipid handling system through upregulation of ATP binding cassette transporter (ABC)A1, a protein involved in macrophage lipid efflux. Further, IL-6 can inhibit other inflammatory cytokines. Based on its possible role in accelerating atherosclerosis, blockade of IL-6 action with the antibody tocalizumab, a treatment for rheumatoid arthritis and juvenile rheumatoid arthritis, has been evaluated as an atheroprotective agent, but studies are inconclusive. This review discusses multiple aspects of IL-6 effects on parameters related to development of atherosclerosis and highlights their manifestations in cell culture, murine models and human studies.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"33 1","pages":"14 - 23"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"65","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2017.1319787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 65

Abstract

ABSTRACT Interleukin-6 (IL-6) is a unique pleiotropic cytokine exhibiting both pro- and anti-inflammatory properties depending on the target cell type. Plasma IL-6 levels are associated with cardiovascular risk. IL-6 elevation in atherosclerosis results in effects on multiple cells involved in lipid processing and plaque formation. IL-6 is also the primary determinant of acute phase protein production. IL-6 has a number of properties that foster development of cardiovascular disease. These include activation of endothelial cells, pro-thrombotic effects on platelets and promotion of smooth muscle proliferation and macrophage lipid accumulation. Despite these overall unfavourable effect on cells involved in atheroma formation, IL-6 also has a positive impact on the lipid handling system through upregulation of ATP binding cassette transporter (ABC)A1, a protein involved in macrophage lipid efflux. Further, IL-6 can inhibit other inflammatory cytokines. Based on its possible role in accelerating atherosclerosis, blockade of IL-6 action with the antibody tocalizumab, a treatment for rheumatoid arthritis and juvenile rheumatoid arthritis, has been evaluated as an atheroprotective agent, but studies are inconclusive. This review discusses multiple aspects of IL-6 effects on parameters related to development of atherosclerosis and highlights their manifestations in cell culture, murine models and human studies.

查看原文本刊更多论文

白细胞介素-6在动脉粥样硬化中的作用:致动脉粥样硬化还是保护动脉粥样硬化?

白细胞介素-6 (IL-6)是一种独特的多效细胞因子，根据靶细胞类型表现出促炎和抗炎特性。血浆IL-6水平与心血管风险相关。动脉粥样硬化中IL-6升高对参与脂质加工和斑块形成的多种细胞产生影响。IL-6也是急性期蛋白产生的主要决定因素。IL-6具有许多促进心血管疾病发展的特性。这些包括内皮细胞的激活，对血小板的促血栓作用，促进平滑肌增殖和巨噬细胞脂质积累。尽管对参与动脉粥样硬化形成的细胞有这些总体上不利的影响，IL-6也通过上调ATP结合盒转运蛋白(ABC)A1(一种参与巨噬细胞脂质外溢的蛋白质)对脂质处理系统有积极的影响。此外，IL-6还能抑制其他炎症细胞因子。基于其可能在加速动脉粥样硬化中的作用，抗体tocalizumab阻断IL-6的作用，用于治疗类风湿性关节炎和幼年类风湿性关节炎，已被评估为一种动脉粥样硬化保护剂，但研究尚无定论。本文从多个方面讨论了IL-6对动脉粥样硬化发展相关参数的影响，并重点介绍了其在细胞培养、小鼠模型和人体研究中的表现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.